About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CLDX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202 · Chronic Spontaneous Urticaria
barzolvolimab, Matching placebo
CLDX
Celldex Therapeutics
Phase 3Active, not recruiting976Aug 4, 2026Registry ↗
Nov 12, 2026A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023 · Chronic Spontaneous Urticaria
barzolvolimab, Matching placebo
CLDX
Celldex Therapeutics
Phase 3Active, not recruiting963Aug 12, 2026Registry ↗
Nov 2, 2026A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults…
NCT07266402 · Chronic Inducible Urticaria, Cold Urticaria
Barzolvolimab, Matching Placebo
CLDX
Celldex Therapeutics
Phase 3Recruiting240Jun 2028Registry ↗
Nov 2, 2026Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic S…
NCT07256392 · Chronic Spontaneous Urticaria
barzolvolimab, Standard of Care
CLDX
Celldex Therapeutics
Phase 3Enrolling by invitation1,370Sep 2028Registry ↗
Aug 11, 2026A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552 · Atopic Dermatitis
Barzolvolimab, Matching placebo
CLDX
Celldex Therapeutics
Phase 2Active, not recruiting131May 6, 2026Registry ↗
Aug 4, 2026A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750 · Prurigo Nodularis
barzolvolimab, Matching Placebo
CLDX
Celldex Therapeutics
Phase 2Active, not recruiting140Mar 17, 2026Registry ↗
Jul 2, 2026A Study of CDX-622 in Participants With Mild to Moderate Asthma
NCT07330778 · Mild to Moderate Asthma
CDX-622
CLDX
Celldex Therapeutics
Phase 1Recruiting12Mar 2027Registry ↗
May 27, 2026A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT05774184 · Eosinophilic Esophagitis
barzolvolimab, Matching Placebo
CLDX
Celldex Therapeutics
Phase 2Completed86Jun 4, 2025Registry ↗
May 4, 2026A Phase I Study of CDX-622
NCT06650761 · Healthy Participants
CDX-622, Normal Saline
CLDX
Celldex Therapeutics
Phase 1Completed85Apr 24, 2026Registry ↗
Nov 6, 2025A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT05405660 · Chronic Inducible Urticaria
barzolvolimab, Matching Placebo
CLDX
Celldex Therapeutics
Phase 2Completed196Jun 12, 2024Registry ↗
Jun 15, 2025A Study of CDX-585 in Patients With Advanced Malignancies
NCT05788484 · Non-small Cell Lung Cancer, Gastric Cancer
CDX-585
CLDX
Celldex Therapeutics
Phase 1Completed20May 21, 2025Registry ↗
Mar 26, 2025A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT05368285 · Chronic Spontaneous Urticaria
barzolvolimab, Matching Placebo
CLDX
Celldex Therapeutics
Phase 2Completed208Sep 28, 2023Registry ↗
Mar 28, 2024A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT03329950 · Melanoma, Non-small Cell Lung Cancer
CDX-1140, CDX-301
CLDX
Celldex Therapeutics
Phase 1Completed132Sep 13, 2022Registry ↗
Feb 7, 2024Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem…
NCT05017298 · Corona Virus Infection, Covid19
Allogeneic adipose-derived stem cells
CLDX
Celltex Therapeutics Corporation
Phase 2Not yet recruiting30Nov 1, 2024Registry ↗
Feb 7, 2024Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
NCT04855955 · Alzheimer Disease
Adipose-Derived Mesenchymal Stem Cells
CLDX
Celltex Therapeutics Corporation
—No longer available——Registry ↗
Aug 14, 2023A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT04944862 · Prurigo Nodularis
CDX-0159, Normal saline
CLDX
Celldex Therapeutics
Phase 1Completed24Jul 31, 2023Registry ↗
Jul 19, 2023A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT04538794 · Chronic Spontaneous Urticaria
CDX-0159, Normal Saline
CLDX
Celldex Therapeutics
Phase 1Completed45Jan 17, 2023Registry ↗
Jun 18, 2023A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT04440943 · Non-small Cell Lung Cancer, Breast Cancer
CDX-527
CLDX
Celldex Therapeutics
Phase 1Completed27Apr 6, 2023Registry ↗
May 17, 2023A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients Wi…
NCT04548869 · Cold Urticaria, Cold Contact Urticaria
CDX-0159
CLDX
Celldex Therapeutics
Phase 1Completed41Dec 16, 2022Registry ↗
Apr 18, 2023Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
NCT04448106 · Osteoarthritis, Knee, Osteoarthritis, Hip
Celltex- AdMSCs
CLDX
Celltex Therapeutics Corporation
Phase 2Unknown300Aug 1, 2024Registry ↗
Apr 18, 2023Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
NCT04428801 · COVID-19
autologous adipose-derived stem cells
CLDX
Celltex Therapeutics Corporation
Phase 2Unknown200Sep 2024Registry ↗
Apr 18, 2023Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
NCT04170426 · Rheumatoid Arthritis
autologous adipose derived stem cells
CLDX
Celltex Therapeutics Corporation
Phase 1/2Not yet recruiting54Dec 2024Registry ↗
Apr 3, 2023A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcino…
NCT03254927 · Advanced Head and Neck Squamous Cell Carcinoma
CDX-3379 and cetuximab
CLDX
Celldex Therapeutics
Phase 2Terminated30Sep 16, 2020Registry ↗
Jan 21, 2022A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
NCT05031624 · Healthy Subjects
CDX-0159, Normal saline
CLDX
Celldex Therapeutics
Phase 1Completed32Jan 14, 2022Registry ↗
Jul 7, 2020A Phase 1 Study of CDX-0159
NCT04146129 · Healthy Subjects
CDX-0159, Normal saline
CLDX
Celldex Therapeutics
Phase 1Completed32Apr 6, 2020Registry ↗
Jun 4, 2020A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and O…
NCT02837991 · Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma
CDX-014
CLDX
Celldex Therapeutics
Phase 1Terminated16Nov 16, 2018Registry ↗
Feb 17, 2020A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT01498328 · Glioblastoma, Small Cell Glioblastoma
Bevacizumab, Rindopepimut (CDX-110) with GM-CSF
CLDX
Celldex Therapeutics
Phase 2Completed127Apr 2015Registry ↗
Feb 13, 2020A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Ca…
NCT01094496 · Bladder Cancer
CDX-1307 Vaccine Regimen, Chemotherapy
CLDX
Celldex Therapeutics
Phase 2Terminated3Jul 2011Registry ↗
Dec 9, 2019A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in…
NCT02335918 · Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovari…
Combination of varlilumab and nivolumab
CLDX
Celldex Therapeutics
Phase 1/2Completed175Dec 12, 2018Registry ↗
Sep 6, 2019A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients…
NCT02302339 · Melanoma
glembatumumab vedotin, glembatumumab vedotin and varlilumab
CLDX
Celldex Therapeutics
Phase 2Terminated132Jun 14, 2018Registry ↗
Aug 1, 2019A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
NCT02473731 · Squamous Cell Carcinoma of the Head and Neck
KTN3379
CLDX
Celldex Therapeutics
Phase 1Completed12Sep 22, 2016Registry ↗
Jun 12, 2019A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Sol…
NCT02642016 · Advanced Cancer
CDX-0158 (formerly known as KTN-0158)
CLDX
Celldex Therapeutics
Phase 1Completed28Jan 30, 2018Registry ↗
Mar 8, 2019Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple…
NCT01997333 · Metastatic gpNMB Over-expressing Triple Negative Breast Can…
CDX-011, Capecitabine
CLDX
Celldex Therapeutics
Phase 2Completed327Nov 30, 2017Registry ↗
Jul 26, 2018A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell C…
NCT02386111 · Carcinoma, Renal Cell, Kidney Diseases
Combination of varlilumab and sunitinib
CLDX
Celldex Therapeutics
Phase 1Terminated17Aug 2017Registry ↗
May 21, 2018Individual Patient Expanded Access-Glembatumumab Vedotin
NCT03067935 · Metastatic gpNMB Expressing Triple Negative Breast Cancer
glembatumumab vedotin
CLDX
Celldex Therapeutics
—No longer available——Registry ↗
Apr 30, 2018A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT02543645 · Carcinoma, Renal Cell, Kidney Diseases
Combination of Varlilumab and Atezolizumab
CLDX
Celldex Therapeutics
Phase 1Terminated18Apr 2017Registry ↗
Jan 31, 2018A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT01460134 · CD27 Expressing B-cell Malignancies for Example Hodgkin's L…
CDX-1127, CDX-1127
CLDX
Celldex Therapeutics
Phase 1Completed90Dec 2015Registry ↗
Jan 16, 2018Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT01480479 · Glioblastoma, Small Cell Glioblastoma
Rindopepimut (CDX-110) with GM-CSF, Temozolomide
CLDX
Celldex Therapeutics
Phase 3Completed745Nov 2016Registry ↗
Jan 16, 2018Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
NCT00458601 · Malignant Glioma
CDX-110 with GM-CSF, Temozolomide
CLDX
Celldex Therapeutics
Phase 2Completed82Nov 2010Registry ↗
Oct 18, 2017Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
NCT03068650 · Recurrent GBM
rindopepimut
CLDX
Celldex Therapeutics
—No longer available——Registry ↗
Sep 5, 2017Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemura…
NCT02456701 · Thyroid Cancer
KTN3379, vemurafenib
CLDX
Celldex Therapeutics
Phase 1Completed7Oct 13, 2016Registry ↗
Jul 24, 2017A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advan…
NCT02014909 · Advanced Cancer
KTN3379
CLDX
Celldex Therapeutics
Phase 1Completed64May 25, 2017Registry ↗
Jul 2, 2017A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT01156753 · Breast Cancer
CDX-011, "Investigator's Choice" chemotherapy
CLDX
Celldex Therapeutics
Phase 2Completed120Oct 2012Registry ↗
Jun 27, 2017A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT01465139 · Healthy
CDX-301
CLDX
Celldex Therapeutics
Phase 1Completed30Nov 2012Registry ↗
Apr 7, 2017A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage I…
NCT02413827 · Unresectable Stage III or Stage IV Melanoma
Combination of varlilumab and ipilimumab, Cohort A: varlilu…
CLDX
Celldex Therapeutics
Phase 1/2Terminated9Nov 2, 2016Registry ↗
Apr 7, 2017A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in…
NCT02200380 · For Donors, Related Donors Giving Peripheral Blood Stem Cel…
CDX-301, CDX-301 and plerixafor
CLDX
Celldex Therapeutics
Phase 2Terminated36Mar 2016Registry ↗
Jun 27, 2016A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT00948961 · Advanced Malignancies
CDX-1401 in combination with Resiquimod and/or Poly-ICLC, C…
CLDX
Celldex Therapeutics
Phase 1/2Completed70Jun 2012Registry ↗

47 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:40 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances